Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails-Reference-Cited by-同舟云学术

Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails

Published:2022-04-28 Issue:1 Volume:37 Page:1257-1277
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

Han Seo-Jung¹²^ORCID,Jung Jae Eun¹³,Oh Do Hee¹³,Kim Minsup⁴,Kim Jae-Min⁵⁶,Chung Kyung-Sook⁵,Han Hee-Soo⁵⁷,Lee Jeong-Hun⁵⁷,Lee Kyung-Tae⁵⁶,Jeong Hee Jin¹,Park In Ho⁸⁹^ORCID,Jeon Eunkyeong⁹¹⁰,Shin Jeon-Soo⁸⁹¹⁰^ORCID,Hwang Dongkeun¹,Cho Art E.⁴¹¹,Lee Duck-Hyung³,Sim Taebo¹⁸

Affiliation:

1. Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea

2. Division of Bio-Medical Science & Technology, KIST School, UST, Seoul, Republic of Korea

3. Department of Chemistry, Sogang University, Seoul, Republic of Korea

4. Drug Discovery Institute, inCerebro Co., Ltd., Seoul, Republic of Korea

5. Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea

6. Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, Republic of Korea

7. Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea

8. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea

9. Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea

10. Department of Microbiology, Yonsei University College of Medicine, Seoul, Republic of Korea

11. Department of Bioinformatics, Korea University, Sejong, Republic of Korea

Funder

Korea Institute of Science and Technology

National Research Foundation of Korea

National Research Foundation

National Research Council of Science & Technology

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2022.2068148

Reference58 articles.

1. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

2. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

3. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

4. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

5. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one scaffolds as potent Lck inhibitors as anti-cancer agents;Bioorganic & Medicinal Chemistry Letters;2024-04

2. Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives;European Journal of Medicinal Chemistry;2023-08